GlassScriptPhysician profile
Madhavi Gaddam
NPI 1932193653
$2,779.24
in general payments reported to CMS, 2019-2025
26 companies · $174 in 2025
The $174 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $660 · 2020: $247 · 2021: $311 · 2022: $471 · 2023: $615 · 2024: $302 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,091.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $665.23 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $286.17 | 2019-2025 | |
| Boston Scientific Corporation | $278.53 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $243.60 | 2019-2023 | Trulance |
| Genzyme Corporation | $219.99 | 2023 | |
| Pfizer INC. | $199.77 | 2019-2024 | |
| Braintree Laboratories, INC. | $177.03 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $119.40 | 2019 | |
| Ferring Pharmaceuticals INC. | $85.48 | 2019-2024 | Rebyota |
| Janssen Biotech, INC. | $64.36 | 2023-2024 | Stelara |
| Endo Pharmaceuticals INC. | $53.02 | 2019 | |
| Intercept Pharmaceuticals, INC. | $48.14 | 2019-2021 | |
| Qol Medical, LLC | $45.67 | 2019-2021 | |
| Alfasigma USA, INC. | $37.20 | 2020 | |
| Currax Pharmaceuticals LLC | $35.50 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $33.00 | 2019-2025 | |
| Medtronic, INC. | $27.96 | 2023 | Minimed 780g |
| Lilly USA, LLC | $25.99 | 2024 | Omvoh |
| Tandem Diabetes Care, INC. | $22.69 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Becton, Dickinson and Company | $21.87 | 2022 | |
| Ironwood Pharmaceuticals, INC | $18.58 | 2022 | |
| Capsovision, INC. | $17.49 | 2024 | Capsocam Plus |
| Nestle Healthcare Nutrition INC. | $15.76 | 2020 | |
| Curium US LLC | $12.92 | 2022 | |
| Allergan, INC. | $12.13 | 2019 | |
| Novo Nordisk INC | $11.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madhavi Gaddam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.